Sage Journals: Discover world-class research

Abstract

Objectives:

To assess efficacy and safety outcomes in relationship to the number of injections given during Rezum treatment.

Methods:

A retrospective study was conducted on patients with moderate to severe lower urinary tract symptoms (LUTS) treated with Rezum. Patients were stratified into cohorts based on the number of injections received per lateral prostatic lobe: 1, 2, 3, or 4 injections. International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), International Index of Erectile Function (IIEF)—Erectile Function, IIEF—Orgasmic Function, and adverse events were collected at baseline, 1, 3, 6, and/or 12 months postoperatively.

Results:

A total of 179 patients were included: 58, 91, 22, and 8 patients in the 1, 2, 3, and 4 injections cohorts, respectively. Baseline demographics significantly different across cohorts were age, history of urinary retention, prostate-specific antigen, prostate volume, prostatic urethral length, and presence of median lobe. At 3 months, all cohorts reported significant improvements in IPSS and QoL, which remained durable to 12 months. There were no significant differences in changes in IPSS, QoL, PVR, and IIEF—Erectile and Orgasmic Function between the cohorts at any follow-up. Multiple linear regression showed that the number of injections did not predict changes in IPSS, QoL, PVR, and IIEF—Erectile and Orgasmic Function at any follow-up (p > 0.05) but predicted change in Qmax at 3 months (β = 5.7, p = 0.019). Multiple logistic regression showed that for each additional injection, the odds of gross hematuria, penile burning, penile pain, and dysuria increased by 3.8, 2.6, 2.2, and 3.0, respectively.

Conclusions:

Utilizing less injections represents a safe treatment strategy without compromising Rezum's efficacy in providing durable relief in LUTS.

Get full access to this article

View all access options for this article.

References

Babar

, Loloi

, Tang

, et al. Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review. Low Urin Tract Symptoms, 2022; 14(3):140–154; doi: 10.1111/luts.12435

McVary

, Gange

, Gittelman

, et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol, 2016; 195(5):1529–1538; doi: 10.1016/j.juro.2015.10.181

Mynderse

, Hanson

, Robb

, et al. Rezūm System Water Vapor Treatment for lower urinary tract symptoms/benign prostatic hyperplasia: Validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology, 2015; 86(1):122–127; doi: 10.1016/j.urology.2015.03.021

Garden

, Shukla

, Ravivarapu

, et al. Rezum therapy for patients with large prostates (≥80 g): Initial clinical experience and postoperative outcomes. World J Urol, 2021; 39(8):3041–3048; doi: 10.1007/s00345-020-03548-7

Ines

, Babar

, Singh

, et al. Real-world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. Prostate, 2021; 81(13):956–970; doi: 10.1002/pros.24191

Bole

, Gopalakrishna

, Kuang

, et al. Comparative postoperative outcomes of rezūm prostate ablation in patients with large versus small glands. J Endourol, 2020; 34(7):778–781; doi: 10.1089/end.2020.0177

Bassily

, Wong

, Phillips

, et al. Rezūm for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. Prostate, 2021; 81(14):1049–1054; doi: 10.1002/pros.24201

McVary

, Holland

, Beahrs

. Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 2020; 23(2):303–308; doi: 10.1038/s41391-019-0187-5

McVary

, Gittelman

, Goldberg

, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol, 2021; 206(3):715–724; doi: 10.1097/JU.0000000000001778

10.

Clavien

, Barkun

, de Oliveira

, et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg, 2009; 250(2):187–196; doi: 10.1097/SLA.0b013e3181b13ca2

11.

Aladesuru

, Amankwah

, Elterman

, et al. Pilot study of “less is more” rezum for treatment of BPH. Urology, 2022; 165:256–260; doi: 10.1016/j.urology.2022.01.039

12.

Pathak

, Helo

, McVary

. What's new in Rezūm?. Eur Urol Focus, 2018; 4(1):32–35; doi: 10.1016/j.euf.2018.02.011

13.

Chrysant

. Proactive compared with passive adverse event recognition: Calcium channel blocker-associated edema. J Clin Hypertens (Greenwich), 2008; 10(9):716–722; doi: 10.1111/j.1751-7176.2008.00006.x

14.

Overland

, Vatten

, Rhodes

, et al. Lower urinary tract symptoms, prostate volume and uroflow in norwegian community men. Eur Urol, 2001; 39(1):36–41; doi: 10.1159/000052410

15.

Franciosi

, Koff

, Rhoden

. Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS). Int Urol Nephrol, 2007; 39(3):871–877; doi: 10.1007/s11255-006-9148-8

16.

Kaplan

, Reis

, Staimen

, et al. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?. Br J Urol, 1998; 82(6):804–807; doi: 10.1046/j.1464-410x.1998.00882.x

17.

Foo

. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol, 2017; 4(3):152–157; doi: 10.1016/j.ajur.2017.06.003

18.

Hutch

, Rambo

Jr . A study of the anatomy of the prostate, prostatic urethra and the urinary sphincter system. J Urol, 1970; 104(3):443–452; doi: 10.1016/s0022-5347(17)61756-61757

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.01 MB

Rezum Outcomes in Relationship to Number of Injections: Is Less More?

Abstract

Objectives:

Methods:

Results:

Conclusions:

Get full access to this article

References

Supplementary Material